Skip to main content
Erschienen in: Acta Neuropathologica 1/2010

01.07.2010 | Original Paper

TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease

verfasst von: Eileen H. Bigio, Manjari Mishra, Kimmo J. Hatanpaa, Charles L. White III, Nancy Johnson, Alfred Rademaker, Bing Bing Weitner, Han-Xiang Deng, Steven D. Dubner, Sandra Weintraub, Marsel Mesulam

Erschienen in: Acta Neuropathologica | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The clinical syndrome of primary progressive aphasia (PPA) can be associated with a variety of neuropathologic diagnoses at autopsy. Thirty percent of cases have Alzheimer disease (AD) pathology, most often in the usual distribution, which defies principles of brain–behavior organization, in that aphasia is not symptomatic of limbic disease. The present study investigated whether concomitant TDP-43 pathology could resolve the lack of clinico-anatomic concordance. In this paper, 16 cases of clinical PPA and 10 cases of primarily non-aphasic frontotemporal dementia (FTD), all with AD pathology, were investigated to determine whether their atypical clinical phenotypes reflected the presence of additional TDP-43 pathology. A comparison group consisted of 27 cases of pathologic AD with the typical amnestic clinical phenotype of probable AD. Concomitant TDP-43 pathology was discovered in only three of the FTD and PPA but in more than half of the typical amnestic clinical phenotypes. Hippocampal sclerosis (HS) was closely associated with TDP-43 pathology when all groups were combined for analysis. Therefore, the clinical phenotypes of PPA and FTD in cases with pathologic AD are only rarely associated with TDP-43 proteinopathy. Furthermore, medial temporal TDP-43 pathology is more tightly linked to HS than to clinical phenotype. These findings challenge the current notions about clinicopathologic correlation, especially about the role of multiple pathologies.
Literatur
1.
Zurück zum Zitat Amador-Ortiz C, Lin W-L, Ahmed Z et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445CrossRefPubMed Amador-Ortiz C, Lin W-L, Ahmed Z et al (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer’s disease. Ann Neurol 61:435–445CrossRefPubMed
2.
Zurück zum Zitat Anonymous (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 18:S1–S2 Anonymous (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Neurobiol Aging 18:S1–S2
3.
Zurück zum Zitat Arai T, Hasegawa M, Akiyama H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611CrossRefPubMed Arai T, Hasegawa M, Akiyama H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611CrossRefPubMed
4.
Zurück zum Zitat Arai T, Mackenzie IRA, Hasegawa M et al (2009) Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol 117:125–136CrossRefPubMed Arai T, Mackenzie IRA, Hasegawa M et al (2009) Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies. Acta Neuropathol 117:125–136CrossRefPubMed
5.
Zurück zum Zitat Baker M, Mackenzie IR, Pickering-Brown SM et al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919CrossRefPubMed Baker M, Mackenzie IR, Pickering-Brown SM et al (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:916–919CrossRefPubMed
6.
Zurück zum Zitat Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMed Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMed
7.
Zurück zum Zitat Cairns NJ, Neumann M, Bigio EH et al (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171:227–240CrossRefPubMed Cairns NJ, Neumann M, Bigio EH et al (2007) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171:227–240CrossRefPubMed
8.
Zurück zum Zitat Cruts M, Gijselinck I, van der Zee J et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924CrossRefPubMed Cruts M, Gijselinck I, van der Zee J et al (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:920–924CrossRefPubMed
9.
Zurück zum Zitat Davidson Y, Kelley T, Mackenzie IR et al (2007) Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 113:521–533CrossRefPubMed Davidson Y, Kelley T, Mackenzie IR et al (2007) Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 113:521–533CrossRefPubMed
10.
Zurück zum Zitat Deng HX, Shi Y, Furukawa Y et al (2006) Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci USA 103:7142–7147CrossRefPubMed Deng HX, Shi Y, Furukawa Y et al (2006) Conversion to the amyotrophic lateral sclerosis phenotype is associated with intermolecular linked insoluble aggregates of SOD1 in mitochondria. Proc Natl Acad Sci USA 103:7142–7147CrossRefPubMed
11.
Zurück zum Zitat Farrer MJ, Hulihan MM, Kachergus JM et al (2008) DCTN1 mutations in Perry syndrome. Nat Genet 41:163–165CrossRef Farrer MJ, Hulihan MM, Kachergus JM et al (2008) DCTN1 mutations in Perry syndrome. Nat Genet 41:163–165CrossRef
12.
Zurück zum Zitat Freeman SH, Spires-Jones T, Hyman BT, Growden JH, Frosch MP (2008) TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol 67:62–67CrossRefPubMed Freeman SH, Spires-Jones T, Hyman BT, Growden JH, Frosch MP (2008) TAR-DNA binding protein 43 in Pick disease. J Neuropathol Exp Neurol 67:62–67CrossRefPubMed
13.
Zurück zum Zitat Fujishiro H, Uchikado H, Arai T et al (2009) Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol 117:151–158CrossRefPubMed Fujishiro H, Uchikado H, Arai T et al (2009) Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol 117:151–158CrossRefPubMed
14.
Zurück zum Zitat Geser F, Winton MJ, Kwong LK et al (2008) Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115:133–145CrossRefPubMed Geser F, Winton MJ, Kwong LK et al (2008) Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Acta Neuropathol 115:133–145CrossRefPubMed
15.
Zurück zum Zitat Hasegawa M, Arai T, Akiyama H et al (2007) TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130:1386–1394CrossRefPubMed Hasegawa M, Arai T, Akiyama H et al (2007) TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130:1386–1394CrossRefPubMed
16.
Zurück zum Zitat Hatanpaa K, Bigio E, Cairns NJ et al (2008) TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a Midwest-Southwest Consortium for FTLD Study. J Neuropathol Exp Neurol 67:271–279CrossRefPubMed Hatanpaa K, Bigio E, Cairns NJ et al (2008) TAR DNA-binding protein 43 immunohistochemistry reveals extensive neuritic pathology in FTLD-U: a Midwest-Southwest Consortium for FTLD Study. J Neuropathol Exp Neurol 67:271–279CrossRefPubMed
17.
Zurück zum Zitat Higashi S, Iseki E, Yamamoto R et al (2007) Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res 1184:284–294CrossRefPubMed Higashi S, Iseki E, Yamamoto R et al (2007) Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer’s disease and dementia with Lewy bodies. Brain Res 1184:284–294CrossRefPubMed
18.
Zurück zum Zitat Hu WT, Josephs KA, Knopman DS et al (2008) Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 116:215–220CrossRefPubMed Hu WT, Josephs KA, Knopman DS et al (2008) Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol 116:215–220CrossRefPubMed
19.
Zurück zum Zitat Josephs KA, Holton JL, Rossor MN et al (2004) Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 30:369–373CrossRefPubMed Josephs KA, Holton JL, Rossor MN et al (2004) Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. Neuropathol Appl Neurobiol 30:369–373CrossRefPubMed
20.
Zurück zum Zitat Josephs KA, Whitwell JL, Duffy JR et al (2008) Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 70:25–34CrossRefPubMed Josephs KA, Whitwell JL, Duffy JR et al (2008) Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology 70:25–34CrossRefPubMed
21.
Zurück zum Zitat Josephs KA, Whitwell JL, Knopman DS et al (2008) Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 70:1850–1857CrossRefPubMed Josephs KA, Whitwell JL, Knopman DS et al (2008) Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology 70:1850–1857CrossRefPubMed
22.
Zurück zum Zitat Lipton AM, White CL III, Bigio EH (2004) FTD-MND predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol 108:379–385CrossRefPubMed Lipton AM, White CL III, Bigio EH (2004) FTD-MND predominates in 76 cases of frontotemporal degeneration. Acta Neuropathol 108:379–385CrossRefPubMed
23.
Zurück zum Zitat Mackenzie IRA, Bigio EH, Ince PG et al (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61:427–434CrossRefPubMed Mackenzie IRA, Bigio EH, Ince PG et al (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61:427–434CrossRefPubMed
24.
Zurück zum Zitat Mackenzie IRA, Neumann M, Bigio EH et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4CrossRefPubMed Mackenzie IRA, Neumann M, Bigio EH et al (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1–4CrossRefPubMed
25.
Zurück zum Zitat Mackenzie IR, Shi J, Shaw CL et al (2006) Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol 112:551–559CrossRefPubMed Mackenzie IR, Shi J, Shaw CL et al (2006) Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathol 112:551–559CrossRefPubMed
26.
Zurück zum Zitat McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMed McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMed
28.
Zurück zum Zitat Mesulam M, Wicklund A, Johnson N et al (2008) Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 63:709–719CrossRefPubMed Mesulam M, Wicklund A, Johnson N et al (2008) Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 63:709–719CrossRefPubMed
29.
Zurück zum Zitat Miklossy J, Steele JC, Yu S et al (2008) Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin, and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol 116:625–637CrossRefPubMed Miklossy J, Steele JC, Yu S et al (2008) Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin, and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol 116:625–637CrossRefPubMed
30.
Zurück zum Zitat Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), II: standardization of neuropathological assessment of Alzheimer’s disease. Neurology 41:479–486PubMed Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), II: standardization of neuropathological assessment of Alzheimer’s disease. Neurology 41:479–486PubMed
31.
Zurück zum Zitat Munoz DG, Woulfe J, Kertesz A (2007) Argyrophilic thorny astrocyte clusters in association with Alzheimer’s disease pathology in possible primary progressive aphasia. Acta Neuropathol 114:347–357CrossRefPubMed Munoz DG, Woulfe J, Kertesz A (2007) Argyrophilic thorny astrocyte clusters in association with Alzheimer’s disease pathology in possible primary progressive aphasia. Acta Neuropathol 114:347–357CrossRefPubMed
32.
Zurück zum Zitat Nakashima-Yasuda H, Uryu K, Robinson J et al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114:221–229CrossRefPubMed Nakashima-Yasuda H, Uryu K, Robinson J et al (2007) Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol 114:221–229CrossRefPubMed
33.
Zurück zum Zitat Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMed Neary D, Snowden JS, Gustafson L et al (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:1546–1554PubMed
34.
Zurück zum Zitat Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IRA (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922–2931CrossRefPubMed Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IRA (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:2922–2931CrossRefPubMed
35.
Zurück zum Zitat Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IRA (2009) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118:605–616CrossRefPubMed Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IRA (2009) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118:605–616CrossRefPubMed
36.
Zurück zum Zitat Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133CrossRefPubMed Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130–133CrossRefPubMed
37.
Zurück zum Zitat Olivé M, Janué A, Moreno D, Gámez J, Torrejón-Escribano B, Ferrer I (2009) TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 68:262–273CrossRefPubMed Olivé M, Janué A, Moreno D, Gámez J, Torrejón-Escribano B, Ferrer I (2009) TAR DNA-binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 68:262–273CrossRefPubMed
38.
Zurück zum Zitat Probst A, Taylor KI, Tolnay M (2007) Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol 114:335–345CrossRefPubMed Probst A, Taylor KI, Tolnay M (2007) Hippocampal sclerosis dementia: a reappraisal. Acta Neuropathol 114:335–345CrossRefPubMed
39.
Zurück zum Zitat Rohn TT (2008) Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer’s disease. Brain Res 1228:189–198CrossRefPubMed Rohn TT (2008) Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer’s disease. Brain Res 1228:189–198CrossRefPubMed
40.
Zurück zum Zitat Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL (2008) Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington Disease. J Neuropathol Exp Neurol 67:1159–1165CrossRefPubMed Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL (2008) Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington Disease. J Neuropathol Exp Neurol 67:1159–1165CrossRefPubMed
41.
Zurück zum Zitat Uryu K, Nakashima-Yasuda H, Forman MS et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67:555–564CrossRefPubMed Uryu K, Nakashima-Yasuda H, Forman MS et al (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol 67:555–564CrossRefPubMed
42.
Zurück zum Zitat Weihl CC, Temiz P, Miller SE et al (2008) TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psych 79:1186–1189CrossRef Weihl CC, Temiz P, Miller SE et al (2008) TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psych 79:1186–1189CrossRef
44.
Zurück zum Zitat Wider C, Dickson DW, Stoessl AJ et al (2008) Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord 15:281–286CrossRefPubMed Wider C, Dickson DW, Stoessl AJ et al (2008) Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord 15:281–286CrossRefPubMed
Metadaten
Titel
TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease
verfasst von
Eileen H. Bigio
Manjari Mishra
Kimmo J. Hatanpaa
Charles L. White III
Nancy Johnson
Alfred Rademaker
Bing Bing Weitner
Han-Xiang Deng
Steven D. Dubner
Sandra Weintraub
Marsel Mesulam
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Acta Neuropathologica / Ausgabe 1/2010
Print ISSN: 0001-6322
Elektronische ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-010-0681-2

Weitere Artikel der Ausgabe 1/2010

Acta Neuropathologica 1/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.